Leniolisib is an orally administered kinase inhibitor that is used to treat adults and children 12 years of age or older with Activated Phosphoinositide-3-kinase-delta Syndrome (APDS), an extremely rare, inherited immunodeficiency disease. Leniolisib has had very limited clinical use but has not been reported to cause elevations in liver enzymes and has not been linked to episodes of clinically apparent liver injury.
来尼洛西布是一种口服激酶抑制剂，用于治疗患有活化磷脂酰肌醇-3-激酶δ综合征（APDS）的12岁及以上成人和儿童，APDS是一种极其罕见的遗传性免疫缺陷疾病。来尼洛西布的临床应用非常有限，但尚未有报道称其会导致肝酶升高，也未发现与明显的临床肝损伤发作有关。
